Targeted delivery of cisplatin to prostate cancer cells was feasible via targeting PSMA using the aptamer attached to PLGA-PEG NPs. In vitro cytotoxicity assay showed that PSMA aptamer targeted cisplatin encapsulated NPs are 80 times more toxic than free cisplatin in the human prostate epithelial cells (LNCaP) [72]. Here, FOLH1 is linked to prostate carcinoma.